Clinical Trials List
2023-12-01 - 2029-04-30
Phase III
Recruiting9
ICD-10C79.10
Secondary malignant neoplasm of unspecified urinary organs
ICD-10C79.11
Secondary malignant neoplasm of bladder
ICD-10C79.19
Secondary malignant neoplasm of other urinary organs
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9198.1
Secondary malignant neoplasm of other urinary organs
-
Trial Applicant
Pharmaceutical Research Associates Taiwan Inc.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Che-Yuan Hu 無
- Jui-Hung Tsai 無
- Yuh-Shyan Tsai 無
- Jiann-Hui Ou 無
- Kwang-Yu Chang 無
- 鍾秉軒 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王樹吉 無
- 洪晟鈞 無
- 梅承恩 無
- 楊涵中 無
- Shian-Shiang Wang 無
- Chia-Yen Lin 無
- 張瓈文 無
- Cheng-Kuang Yang 無
- 賴谷順 無
- 林雁婷 無
- 張家程 無
- Chuan-Shu Chen 無
- 廖博崎 無
- JU-CHUAN HU 無
- Cheng-Che Chen 無
- 裘坤元 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- CHUNG-HSIN CHEN 無
- JHE-CYUAN GUO 無
- Yeong-Shiau Pu 無
- JIAN-HUA HONG 無
- - - 無
- Ying-Chun Shen 無
- - - 無
- FU-JEN HSUEH 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hong-Cheng Gan 無
- 張鈞弼 無
- Kai-Jie Yu 無
- I-hung Shao 無
- PO-HUNG LIN 無
- See-Tong Pang 無
- Yung-Chang Lin 無
- Rita cheng 無
- Po-Jung Su 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wei-Ching Lin 無
- Chi-Rei Yang 無
- Che-Hung Lin 無
- Chi-Ping Huang 無
- 鄭富銘 無
- Hsi-Chin Wu 無
- Han Chang 無
- 蔡禮賢 無
- Su-Peng Yeh 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hsiang Ying Lee 無
- 張顥瀚 無
- Hung-Lung Ke 無
- 阮雍順 無
- Tsu-Ming Chien 無
- Ching-Chia Li 無
- Sheng-Chen Wen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
22 participants
-
Global
400 participants
